Less than a tenth of individuals eligible to benefit from obesity jabs including Wegovy are able to get them, states the WHO as it publishes its initial recommendations on the therapies.
Considering more than one billion individuals worldwide currently classified as obese, it is advocating for increased and just access to these injectable treatments.
Based on projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidelines acknowledges that obesity is a chronic disease that can be treated with comprehensive and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are key barriers to broad availability to the injections that can aid individuals in losing substantial body mass, explains the body.
Skinny Jab Scarcity
Even under the present most optimistic outlook, the manufacturing of these medications might only reach approximately 100 million people – fewer than 10% of the global need, as stated by the WHO.
The recommendation urges governments and firms to increase access, through approaches like patent sharing.
A patent on a key compound – the primary component of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.
The Way Obesity Jabs Work
GLP-1 drugs imitate a natural hormone to reduce digestion speed, suppress the appetite and increase feelings of fullness so users eat less.
Individuals typically begin shedding pounds within a few weeks of starting on the regular doses.
Studies points to users may put most of the weight back on within a year of stopping the medication, because their normal food cravings come back.
Being carrying excess weight elevates your risk for developing diseases, such as diabetes, cardiovascular issues, stroke, and specific cancers.
Obesity affects people in all nations and was responsible for 3.7 million deaths worldwide in 2024, per the WHO.
